Tag
This study evaluates how clonal hematopoiesis of indeterminate potential (CHIP) and pre-treatment neutropenia affect clinical outcomes and toxicities in patients undergoing CAR-T therapy for hematologic cancers, revealing nuanced risks for
Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitori
Single-cell transcriptomic profiling of ide-cel CAR-T products reveals that intrinsic NF-κB signaling in CD4 CAR-T cells correlates with durable remission in relapsed/refractory multiple myeloma, marking T-cell fitness and potential therape
This study evaluates the outcomes and critical factors influencing the success of tisagenlecleucel therapy for children and young adults with B-cell acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplant across Euro
This review synthesizes real-world data from the DESCAR-T registry on CAR T-cell therapy response kinetics in large B-cell lymphoma, highlighting the prognostic impact of early response patterns and factors influencing conversion from parti
This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and
EBMT’s 2024 report marks over one million reported stem cell transplants and continued rapid CAR-T growth, highlighting shifts in indications, donor use, and access across Europe.
The updated CARTITUDE-4 analysis demonstrates that cilta-cel significantly improves overall survival and progression-free survival compared to standard therapies in lenalidomide-refractory multiple myeloma patients after the first relapse,
This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.
Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patien
CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a
A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.
